(Q34957256)

5 August 2017

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy (English)

1 reference

5 August 2017

1 reference

1 reference

Huldrych F Günthard

12

0 references

Paul Klenerman

15

object named as

Paul Klenerman

1 reference

5 August 2017

11

Hansjakob Furrer

1 reference

5 August 2017

1

Silvana Gaudieri

1 reference

5 August 2017

16

Simon Mallal

1 reference

5 August 2017

Andri Rauch

2

1 reference

ORCID Public Data File 2021

Geoff McCaughan

6

object named as

Geoff McCaughan

1 reference

5 August 2017

Katja Pfafferott

3

1 reference

5 August 2017

Eleanor Barnes

4

1 reference

5 August 2017

Wendy Cheng

5

1 reference

5 August 2017

Nick Shackel

7

1 reference

5 August 2017

Gary P Jeffrey

8

1 reference

5 August 2017

Lindsay Mollison

9

1 reference

5 August 2017

Ross Baker

10

1 reference

5 August 2017

Elizabeth Freitas

13

1 reference

5 August 2017

Isla Humphreys

14

1 reference

5 August 2017

Ian James

17

1 reference

5 August 2017

Stuart Roberts

18

1 reference

5 August 2017

David Nolan

19

1 reference

5 August 2017

Michaela Lucas

20

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

5 August 2017

1 reference

5 August 2017

49

1 reference

5 August 2017

4

1 reference

5 August 2017

1069-1082

1 reference

The way forward in HCV treatment--finding the right path

5 August 2017

1 reference

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

CD8 Epitope Escape and Reversion in Acute HCV Infection

21 January 2018

1 reference

Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection

21 January 2018

1 reference

Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution

21 January 2018

1 reference

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution

21 January 2018

1 reference

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

21 January 2018

1 reference

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

21 January 2018

1 reference

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

Challenges and successes in developing new therapies for hepatitis C.

21 January 2018

1 reference

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

21 January 2018

1 reference

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro

21 January 2018

1 reference

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

21 January 2018

1 reference

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro

21 January 2018

1 reference

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

21 January 2018

1 reference

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

21 January 2018

1 reference

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

21 January 2018

1 reference

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

21 January 2018

1 reference

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.22773

1 reference

5 August 2017

1 reference